Calcineurin inhibitors and chronic renal allograft dysfunction: Not enough or too much?

Transplantation Reviews

Volumn 15, Issue 2, 2001, Pages 82-92

  Paul, Leendert C ^a   Sijpkens, Yvo W J ^a   De Fijter, Johan W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4544286194     PISSN: 0955470X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-470X(05)80003-5     Document Type: Article

References (122)

1. Sijpkens YWJ, Doxiadis UN, De Fijter JW, et al: Sharing crossreactive groups (CREG) of MHC class I antigens improves long-term graft survival. Kidney Int 1999, 56:1920
2. Johnson RWG: The clinical impact of nephrotoxicity in renal transplantation. Transplantation 2000, 69(suppl):S14
3. Dimény E, Wahlberg J, Larsson E, et al: Can histopathological findings in early renal allograft biopsies identify patients at risk for chronic vascular rejection? Clin Transplant 1995, 9:79
4. Rush DN, Jeffery JR, Gough J: Sequential protocol biopsies in renal transplant patients: Clinico-pathological correlations using the Banff schema. Transplantation 1995, 59:511
5. Isoniemi HM, Krogerus L, Von Willebrand E, et al: Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992, 41:155
6. Belitsky P, Levy GA, Johnston A: Neoral absorption profiling: An evolution in effectiveness. Transplant Proc 2000, 32(suppl 3A):S45
7. Paul LC, Häyry P, Foegh M, et al: Diagnostic criteria for chronic rejection/accelerated graft atherosclerosis in heart and kidney transplants: Joint proposal from the Fourth Alexis Carrel Conference on Chronic Rejection and Accelerated Arteriosclerosis in Transplanted Organs. Transplant Proc 1993, 25:2022
8. Riggio RR, Haschemeyer R, Suthanthiran M, et al: Predictability of renal allograft failure time in long-term survivors: A hypothesis. Transplant Proc 1985, 17:2311
9. Kasiske BL, Heim-Duthoy KL, Tortorice KL, et al: The variable nature of chronic declines in renal allograft function. Transplantation 1991, 51:330
10. Flechner SM, Modlin CS, Serrano DP, et al: Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996, 62:1235
11. Almond PS, Matas A, Gillingham KJ, et al: Risk factors for chronic rejection in renal allograft recipients. Transplantation 1993, 55:752
12. Massy ZA, Guijarro C, Wiederkehr MR, et al: Chronic renal allograft rejection: Immunologic and nonimmunologic risk factors. Kidney Int 1996, 49:518
13. Barrientos A, Portoles J, Herrero JA, et al: Glomerular hyperfiltration as a nonimmunologic mechanism of progression of chronic renal rejection. Transplantation 1994, 57:753
14. Cheigh JS, Mouradian J, Soliman M, et al: Focal segmental glomerulosclerosis in renal transplants. Am J Kidney Dis 1983, 2:449
15. Hamburger J, Crosnier J, Dormont JA: Observations in patients with a well tolerated homotransplanted kidney. Ann N Y Acad Sci 1964, 120:558
16. Olsen TS: Pathology of allograft rejection, in Burdick JF, Racusen LC, Solez K, et al (eds): Kidney Transplant Rejection. Diagnosis and Treatment. New York, Dekker, 1992, p333
17. Andresdottir MB, Assmann KJM, Koene RAP, et al: Immunohistological and ultrastructural differences between recurrent type I membranoproliferative glomerulonephritis and chronic transplant glomerulopathy. Am J Kidney Dis 1998, 32:582
18. Monga G, Mazzucco G, Messina M, et al: Intertubular capillary changes in kidney allografts: A morphologic investigation on 61 renal specimens. Mod Pathol 1992, 5:125
19. Ivanyi B, Fahmy H, Szenohradszky P, et al: Peritubular capillary basement membrane changes in chronic renal allograft rejection. Transplant Proc 2001 (in press)
20. Takeuchi O, Oikawa T, Koyama K, et al: Multilayering of peritubular capillary is a specific diagnostic criterion for immunologic chronic rejection: Does a humoral factor contribute to the pathogenesis of peritubular capillary lesions in chronic rejection? Transplant Proc 2000, 32:306
21. Collins AB, Schneeberger EE, Pascual MA, et al: Complement activation in acute humoral renal allograft rejection: Diagnostic significance of C4d deposits in peritubular capillaries. J Am Soc Nephrol 1999, 10:2208
22. Mauiyyedi S, Della Pelle P, Saidman S, et al: Identifying antibody mediated chronic renal allograft rejection by C4d in peritubular capillaries [abstract]. XVIII International Congress of the Transplantation Society 2000, Rome, 2000: 216A
23. Tilney NL, Paul LC: Antigen-independent events leading to chronic graft dysfunction, in Tilney NL, Strom TB, Paul LC (eds): Transplantation Biology: Cellular and Molecular Aspects. Philadelphia, Lippincott-Raven, 1996, p 629
24. Paul LC, Tilney NL: Alloantigen-dependent events in chronic rejection, in Tilney NL, Strom TB, Paul LC (eds): Transplantation Biology. Cellular and Molecular Aspects. Philadelphia, Lippincott-Raven, 1996, p 567
25. Cramer DV, Chapman FA, Wu GD, et al: Cardiac transplantation in the rat. II. Alteration of the severity of donor graft arteriosclerosis by modulation of the host immune response. Transplantation 1990, 50:554
26. Azuma H, Chandraker A, Nadeau K, et al: Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A 1996, 93:12439
27. Shi C, Lee W-S, He Q, et al: Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci U S A 1996, 93:4051
28. Russell PS, Chase CM, Colvin RB: Alloantibody- and T cell-mediated immunity in the pathogenesis of transplant arteriosclerosis. Lack of progression to sclerotic lesions in B cell-deficient mice. Transplantation 1997, 64:1531
29. Takemoto SK, Terasaki PI, Gjertson DW, et al: Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000, 343:1078
30. Paul LC: Antibodies and chronic organ graft rejection. Curr Opin Organ Transplant 1999, 4:23
31. Vella JP, Spadafora-Ferreira M, Murphy B, et al: Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997, 64:795
32. Zietse R, Balk AH, Dorpel MA, et al: Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994, 14:1
33. Greenberg A, Thompson ME, Griffith BJ, et al: Cyclosporine nephrotoxicity in cardiac allograft patients: Seven year follow up. Transplantation 1990, 50:589
34. Young EW, Ellis CN, Messana JM, et al: A prospective study of renal structure and function in psoriasis patients treated with cyclosporine. Kidney Int 1994, 46:1216
35. Henny FC, Kleinbloesem CH, Moolenaar AJ, et al: Pharmacokinetics and nephrotoxicity of cyclosporine A in renal transplant recipients. Transplantation 1985, 40:261
36. Myers BD, Newton L: Cyclosporine-induced chronic renal nephropathy: An obliterative microvascular renal injury. J Am Soc Nephrol 1991, 2(suppl):S45
37. English J, Evan A, Houghton DC, et al: Cyclosporine-induced acute renal dysfunction in the rat. Evidence of arteriolar vasoconstriction with preservation of tubular function. Transplantation 1987, 44:135
38. Benigni A, Bruzzi I, Mister M, et al: Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney Int 1999, 55:674
39. Kon SP, Templar J, Dodd SM, et al: Diagnostic contribution of renal allograft biopsies at various intervals after transplantation. Transplantation 1997, 63:547
40. Mihatsch MJ, Ryffel B, Gudat F: The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995, 48(suppl):S63
41. Cosio FG, Frankel WL, Pelletier RP, et al: Focal segmental glomerulosclerosis in renal allografts with chronic nephropathy: Implications for graft survival. Am J Kidney Dis 1999, 34:731
42. Mihatsch MJ, Thiel G, Ryffel B: Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988, 20(suppl 3):S63
43. Dell'Antonio G, Randhawa PS: "Striped" pattern of medullary ray fibrosis in allograft biopsies from kidney transplant recipients maintained on tacrolimus. Transplantation 1999, 67:484
44. Feutren G, Mihatsch MJ, International Kidney Biopsy Registry of Cyclosporine in Autoimmune Disease: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992, 326:1654
45. Myers B: Cyclosporine nephrotoxicity. Kidney Int 1986, 30: 964
46. Myers BD, Newton L, Boshkos C, et al: Chronic injury to human microvessels with low dose cyclosporine therapy. Transplantation 1988, 46:694
47. Bertani T, Ferrazzi P, Schieppati A, et al: Nature and extent of glomerular injury by cyclosporine in heart transplant patients. Kidney Int 1991, 40:243
48. Fisher NC, Nightingale PC, Gunson BK, et al: Chronic renal failure following liver transplantation. Transplantation 1998, 66:59
49. Dieterle A, Gratwohl A, Nizze H, et al: Chronic cyclosporine-associated nephrotoxicity in bone marrow transplant patients. Transplantation 1990, 49:1093
50. Tinawi M, Miller L, Bastani B: Renal function in cardiac transplant recipients: Retrospective analysis of 133 consecutive patients in a single center. Clin Transplant 1997, 11:1
51. Herrero JI, Quiroga J, Sangro B, et al: Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transpl Surg 1999, 5:414
52. Aleksic I, Baryalei M, Busch T, et al: Improvement of impaired renal function in heart transplant recipients treated with mycophenolate mofetil and low-dose cyclosporine. Transplantation 2000, 69:1586
53. Hueso M, Bover J, Serón D, et al: Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with sub-optimal renal function. Transplantation 1998, 66:1727
54. Weir MR, Anderson L, Fink JC, et al: A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997, 64:1706
55. Falkenhain ME, Cosio FG, Sedmak DD: Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996, 62:364
56. Franceschini N, Alpers CE, Bennett WM, et al: Cyclosporine arteriopathy: Effects of drug withdrawal. Am J Kidney Dis 1998, 32:247
57. Collins BS, Davis CL, Marsh CL, et al: Reversible cyclosporine arteriolopathy. Transplantation 1992, 54:732
58. Shihab FS, Bennett WM, Tanner AM, et al: Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1998, 64:1829
59. Remuzzi G, Perico N: Cyclosporine-induced renal dysfunction in experimental animals and humans. Kidney Int 1995, 48(suppl 52):S70
60. Lafayette RA, Mayer G, Meyer TW: The effects of blood pressure reduction on cyclosporine nephrotoxicity in the rat. J Am Soc Nephrol 1993, 3:1892
61. Andoh TF, Gardner MP, Bennett WM: Protective effects of dietary L-arginine supplementation on chronic cyclosporine nephrotoxicity. Transplantation 1997, 64:1236
62. Shihab FS, Andoh TF, Tanner AM, et al: Sodium depletion enhances fibrosis and the expression of TFG-beta-1 and matrix proteins in experimental chronic cyclosporine nephropathy. Am J Kidney Dis 1997, 30:71
63. Wolf G, Thaiss F, Stahl RAK: Cyclosporine stimulates expression of transforming growth factor-β in renal cells. Transplantation 1995, 60:237
64. Wolf G, Killen PD, Neilson EG: Cyclosporin A stimulates transcription and procollagen secretion in tubulointerstitial fibroblasts and proximal tubular cells. J Am Soc Nephrol 1990, 1:918
65. Shihab FS, Bennett WM, Tanner AM, et al: Angiotensin II blockade decreases TGF-beta-1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997, 52:660
66. Nankivell BJ, Hibbins M, Chapman JR: Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation 1994, 28:271
67. Oellerich M, Armstrong VW, Kahan B, et al: Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: Report of the consensus panel. Ther Drug Monit 1995, 17:642
68. Meyer MM, Munar M, Udeaja J, et al: Efficacy of area under the curve cyclosporine monitoring in renal transplantation. J Am Soc Nephrol 1993, 4:1306
69. Kovarik JM, Mueller EA, Richard F, et al: Evidence for earlier stabilization of cyclosporine pharmacokinetics in de novo renal transplant patients receiving a microemulsion formulation. Transplantation 1996, 62:759
70. Mahalati K, Belitsky P, Sketris I, et al: Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999, 68:55
71. Kasiske BL, Heim-Duthoy K, Rao KV, et al: The relationship between cyclosporine pharmacokinetic parameters and subsequent acute rejection in renal transplant recipients. Transplantation 1988, 46:716
72. Lindholm A, Kahan BD: Influence of cyclosporine pharmacokinetic parameters, trough concentration and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993, 54:205
73. Toki K, Kyo M, Takahara S, et al: Clinicopathological evaluation in non-episode biopsies of renal allograft. Transplant Int 2000, 13(suppl 1):S73
74. Mekki Q, Lee C, Aweeka F, et al: Pharmacokinetics of tacrolimus (FK506) in kidney transplant patients [abstract]. Clin Pharmacol Ther 1993, 53:238A
75. Christiaans M, Van Duijnhoven E, Beysens T, et al: Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc 1998, 30:1271
76. Wong KM, Shek CC, Chau KF, et al: Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000, 35:660
77. Takahara S, Kakado Y, Kameoka H, et al: Monitoring of FK506 blood levels in kidney transplant recipients. Transplant Proc 1994, 26:2106
78. Winkler M, Ringe B, Rodeck B, et al: The use of plasma levels for FK506 dosing in liver graft patients. Transplant Int 1994, 7:329
79. Woodle ES, Cronin D, Newell KA, et al: Tacrolimus therapy for refractory acute renal allograft rejection. Definition of the histologic response by protocol biopsies. Transplantation 1996, 62:906
80. De Mattos AM, Norman DJ, Olyaei A, et al: Neoral once versus twice daily dosing - Systemic and renal hemodynamic differences [abstract]. J Am Soc Nephrol 1998, 9:671A
81. Montagnino G, Tarantino A, Maccario M, et al: Long-term results with cyclosporine monotherapy in renal transplant patients: A multivariate analysis of risk factors. Am J Kidney Dis 2000, 35:1135
82. Pirsch JD, Miller J, Deierhoi MH, et al: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997, 63:977
83. Mayer AD, Dmitrewski J, Squifflet JP, et al: Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection - A report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997, 64:436
84. Keown P, Niese D, International Sandimmun Neoral Study Group: Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998, 54:938
85. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine. Transplantation 1998, 66:1736
86. Margreiter R. for the European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group: Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: A randomised multicentre study. 2001 (submitted for publication)
87. Gjertson DW, Cecka JM, Terasaki PI: The relative effects of FK506 and cyclosporine on short- and long-term kidney graft survival. Transplantation 1995, 60:1384
88. Neumayer HH, Farber L, Haller P, et al: Substitution of conventional cyclosporine with a new microemulsion formulation in renal transplant patients: Results after 1 year. Nephrol Dial Transplant 1996, 11:165
89. Frei UA, Neumayer HH, Buchholz B, et al: Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. Transplantation 1998, 65:1455
90. Curtis JJ, Lynn M, Jones PA: Neoral conversion from Sand-immune in maintenance renal transplant patients: An individualized approach. J Am Soc Nephrol 1998, 9:1293
91. Cole E, Keown P, Landsberg D, et al: Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients. Transplantation 1998, 65:505
92. Bartucci M, Koshla B, Fleming-Brooks S, et al: Renal function following conversion from Sandimmune to Neoral in stable renal transplant recipients. J Transplant Coord 1997, 7:78
93. Sijpkens YWJ, Mallat MJK, Siegert CEH, et al: Cyclosporine toxicity after conversion from Sandimmune to Neoral. Clin Nephrol 2001 (in press)
94. Pascual M, Swinford RD, Ingelfinger JR, et al: Chronic rejection and chronic cyclosporin toxicity in renal allografts. Immunol Today 1998, 19:514
95. Dimény E, Tufveson G, Lithell H, et al: The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993, 23:572
96. Kahan BD, Welsh M, Schoenberg L, et al: Variable oral absorption of cyclosporine - A biopharmaceutical risk factor for chronic renal, allograft rejection. Transplantation 1996, 62:599
97. Mihatsch MJ, Steiner K, Abeywickrama KH, et al: Risk factors for the development of chronic cyclosporine nephrotoxicity. Clin Nephrol 1988, 29:165
98. Habib R, Zurowska A, Hinglais N, et al: A specific glomerular lesion of the graft: Allograft glomerulopathy. Kidney Int 1993, 44(suppl 42):S104
99. Hill PA, Main IW, Atkins RC: ICAM-1 and VCAM-1 in human renal allograft rejection. Kidney Int 1995, 47:1383
100. Abrass CK, Berfield AK, Stehman-Breen C, et al: Unique changes in interstitial extracellular matrix composition are associated with rejection and cyclosporine toxicity in human renal allograft biopsies. Am J Kidney Dis 1999, 33:11
101. Navis G, Broekroelofs J, Mannes GPM, et al: Renal hemodynamics after lung transplantation. A prospective study. Transplantation 1996, 61:1600
102. Goldstein DJ, Zuechen N, Sehgal V, et al: Cyclosporine-associated end-stage nephropathy after cardiac transplantation: Incidence and progression. Transplantation 1997, 63: 664
103. Klompmaker IJ, Homan van der Heide JJ, Tegzess AM, et al: Effect of cyclosporin A withdrawal on renal function and renal stimulation in liver transplant patients treated with triple drug immunosuppression for over two years. Nephrol Dial Transplant 1994, 9:1629
104. Gjertson DW: Survival trends in long-term first cadaver-donor kidney transplants, in Terasaki PI, Cecka JM (eds): Clinical Transplants 1991. Los Angeles, UCLA Tissue Typing Laboratory, 1992, p 225
105. Thorogood J, van Houwelingen HC, van Rood JJ, et al: Long-term results of kidney transplantation in Eurotransplant, in Paul LC, Solez K (eds): Organ Transplantation. Long-Term Results. New York, Dekker, 1992, p 33
106. Cecka JM: The UNOS Scientific Renal Transplant Registry, in Cecka JM, Terasaki PI (eds): Clinical Transplants 1998. Los Angeles, UCLA Tissue Typing Laboratory, 1999, p 1
107. Hariharan S, Johnson CP, Bresnahan BA, et al: Improved graft survival after transplantation in the United States, 1988 to 1996. N Engl J Med 2000, 342:605
108. Ojo AO, Meier-Kriesche HU, Hanson JA, et al: Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000, 69:2405
109. Beveridge T, Calne RY, for the European Multicentre Trial Group: Cyclosporine (Sandimmune) in cadaveric renal transplantation: Ten-year follow-up of a multicentre trial. Transplantation 1995, 59:1568
110. European Multicentre Trial Group: European multicentre trial of cyclosporine in renal transplantation: 10-Year follow-up. Transplant Proc 1993, 25:527
111. Ponticelli C, Civati G, Tarantino A, et al: Randomized study with cyclosporine in kidney transplantation: 10-Year follow-up. J Am Soc Nephrol 1996, 7:792
112. Lewis RM: Long-term use of cyclosporine A does not adversely impact on clinical outcomes following renal transplantation. Kidney Int 1995, 48(suppl 52):S75
113. Burke JF, Pirsch JD, Ramos EL, et al: Long-term efficacy and safety of cyclosporine in renal-transplant patients. N Engl J Med 1994, 331:358
114. Opelz G: Effect of maintenance immunosuppressive drag regimen on kidney transplant outcome. Transplantation 1994, 58:443
115. Kasiske BL, Heim-Duthoy K, Ma JZ: Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 1993, 269:395
116. Kasiske BL, Chakkera HA, Louis TA, et al: A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000, 11:1910
117. Hollander AAMJ, Van Saase JLCM, Kootte AMM, et al: Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995, 345:610
118. Montagnino G, Tarantino A, Cesana B, et al: Prognostic factors of long-term allograft survival in 632 CyA-treated recipients of a primary renal transplant. Transplant Int 1997, 10:268
119. Vanrenterghem Y: Approaches to improving long-term outcome. Transplant Proc 1998, 30(suppl 8A):S2
120. Ponticelli C, Aroldi A, Elli A, et al: The clinical status of cadaveric renal transplant patients treated for 10 years with cyclosporine therapy. Clin Transplant 1999, 13:324
121. Matas A, Almond PS, Moss A, et al: Effect of cyclosporine on renal transplant recipients: 12 years follow-up. Clin Transplant 1995, 9:450
122. Mihatsch MJ, Morozumi K, Strom EH, et al: Renal transplant morphology after long-term therapy with cyclosporine. Transplant Proc 1995, 27:39